Human Genome Sciences (HGSI), FivePrime Announce Pact for Licensing Rights to FP-1039 in US, Canada
Tweet
Share
E-mailGet Alerts HGSI Hot Sheet
Join SI Premium – FREE
Human Genome Sciences (Nasdaq: HGSI), FivePrime Therapeutics announce pact for FP-1039 rights in the US and Canada. Human Genome will pay FivePrime an upfront license fee of $500 million; FivePrime will be eligible for up to $45 million in future development milestones.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
